ResMed Launches AirSense 11 PAP Series, Advancing Digital Health in Sleep Apnea Treatment
16 Agosto 2021 - 10:00AM
ResMed, a global leader in digital health and sleep apnea
treatment, (NYSE: RMD, ASX: RMD) today launched AirSense 11,
available first in the U.S., the company’s next-generation PAP
(positive airway pressure) device designed to help hundreds of
millions of people worldwide with sleep apnea1 start and stay on
therapy to treat and manage obstructive sleep apnea.
AirSense 11 includes new features like Personal Therapy
Assistant and Care Check-In designed to provide tailored guidance
to PAP users, helping ease them into therapy and comfortable
nightly use. Other features include the availability of remote
software updates so users can enjoy the latest version of these
tools every night.
“AirSense 11’s new tailored features along with our myAir
patient engagement app help give people the support they need to
use PAP – the gold standard for treating sleep apnea – comfortably
and confidently every night,” said Jim Hollingshead, ResMed
president of Sleep and Respiratory Care. “And when digital health
helps guide patients, it enables clinicians to provide great care
to all their patients more efficiently.”
AirSense 11 features
- Personal Therapy Assistant provides
interactive step-by-step tutorials via the myAir app for patients
to set up their device and acclimate to therapy pressure.
- Care Check-In gives patients tailored guidance
through key milestones in their treatment journey, based on
patients’ responses to simple questions like “How is your therapy”
and “How sleepy did you feel this week?” It’s available in the
myAir app and on the device screen itself. With the patient’s
consent, healthcare providers can also see their patients’
responses in AirView, providing another fast, virtual way to
monitor patients.
- A sleek design, touch screen, and intuitive
menu mimic a smartphone, making it easy to use, designed to support
increased adherence to therapy.
- ResMed’s proprietary therapy algorithms for
AutoSet or APAP (auto-adjusting PAP) that delivers breath-by-breath
therapy adjustments, the AutoSet for Her mode, a setting tailored
to treat the female-specific characteristics of mild to moderate
obstructive sleep apnea, and CPAP (continuous PAP).
- The ability to make over-the-air upgrades
directly to a user’s device – just like you would get on a
smartphone.
Remote and self-monitoring tools that improve
adherence AirSense 11 also gives access to myAir (patient
engagement app) and AirView (remote monitoring platform for
clinicians) – which together help bring overall patient adherence
as high as 87%.2 The myAir app tracks the amount of time patients
spend using CPAP therapy, number of sleep apnea events per hour,
mask leak, and the number of times a mask was removed, providing
nightly data on breathing, coaching tips, and support directly to
their phone.
AirView provides a secure, cloud-based patient management system
for online patient monitoring that enables healthcare professionals
to quickly access patient data, share clinical insights with other
health professionals, improve care and reduce costs related to
patient follow-up.
AirSense 11 is available in the U.S., with other countries to
follow, and is compatible with all ResMed masks. To learn more
about AirSense 11, visit resmed.com/Air11 or speak with your
healthcare provider.
About ResMedAt ResMed (NYSE: RMD, ASX: RMD) we
pioneer innovative solutions that treat and keep people out of the
hospital, empowering them to live healthier, higher-quality lives.
Our digital health technologies and cloud-connected medical devices
transform care for people with sleep apnea, COPD, and other chronic
diseases. Our comprehensive out-of-hospital software platforms
support the professionals and caregivers who help people stay
healthy in the home or care setting of their choice. By enabling
better care, we improve quality of life, reduce the impact of
chronic disease, and lower costs for consumers and healthcare
systems in more than 140 countries. To learn more,
visit ResMed.com and follow @ResMed.
1 Benjafield AV et al. Lancet Respiratory Medicine 2019 2
Malhotra A et al. Chest 2018
For media |
|
|
For investors |
Jayme Rubenstein |
|
|
Amy Wakeham |
+1 858.836.6798 |
|
|
+1 858.836.5000 |
news@resmed.com |
|
|
investorrelations@resmed.com |
Photos accompanying this announcement are available
at:https://www.globenewswire.com/NewsRoom/AttachmentNg/b862bade-ecef-404c-b9c6-49e5bd94a03bhttps://www.globenewswire.com/NewsRoom/AttachmentNg/049845c6-55a7-4af3-a7d7-47ea0bd83309https://www.globenewswire.com/NewsRoom/AttachmentNg/d0cddb81-5c67-4f93-9eb6-5df5f3c495d6https://www.globenewswire.com/NewsRoom/AttachmentNg/fcf003e2-e817-4bcb-9138-69b2d930ce38https://www.globenewswire.com/NewsRoom/AttachmentNg/58f84ecd-68c4-44f0-a21d-0fc072ffeaf7https://www.globenewswire.com/NewsRoom/AttachmentNg/7c29aee1-de55-4002-ace1-87abdf8d071ahttps://www.globenewswire.com/NewsRoom/AttachmentNg/511a949c-2e4f-45c1-803f-73bf731b1787
ResMed (NYSE:RMD)
Gráfico Histórico do Ativo
De Fev 2024 até Mar 2024
ResMed (NYSE:RMD)
Gráfico Histórico do Ativo
De Mar 2023 até Mar 2024